Targeted Therapy for Breast Cancer in India: HER2 Treatment, CDK4/6 Inhibitors, Medicines and Cost

Breast cancer is not one single disease. Two patients may have tumours in the same breast but require very different medicines because their cancer cells have different biological characteristics.

This is why doctors examine more than the size of a tumour or its stage. They also study specific proteins and biomarkers that influence how cancer cells grow. Targeted therapy uses medicines designed to act on these specific features.

For example, some breast cancers produce excessive amounts of a protein called HER2 and may respond to HER2-targeted medicines such as trastuzumab and pertuzumab. Other cancers are hormone receptor-positive and HER2-negative; selected patients may benefit from CDK4/6 inhibitors with hormone therapy. Patients with certain inherited genetic mutations may also be eligible for PARP inhibitors.

India offers access to several targeted cancer medicines through specialist oncology hospitals. These treatments can involve substantial expenses, and not every medicine is suitable for every patient. GAF planning for targeted therapy is $8,000–$30,000 (oral or infusion · months of therapy). Neighbouring molecular targeted therapy is $10,000–$32,000.

Related GAF guides include HER2-positive breast cancer treatment, ER, PR and HER2 results, targeted therapy side effects and the curated pathway targeted therapy in India. Named medical oncologists and medical oncology hospitals can be filtered by city before travel.

Targeted therapy is a type of cancer treatment that acts on specific molecules involved in the growth, division or survival of cancer cells. These molecules may include proteins on cancer cell surfaces, receptors that receive growth signals, enzymes involved in cell division, proteins responsible for DNA repair, and molecular pathways that help cancer cells survive.

Unlike conventional chemotherapy, which affects many rapidly dividing cells, targeted medicines are designed to interfere with particular biological processes. Targeted therapy is not completely free of side effects — some medicines can affect healthy cells or normal body functions.

The choice of medicine depends on the cancer's subtype, stage, biomarker results and previous treatment.

Targeted therapy is recommended only when the patient's cancer has the biological characteristics that make the treatment appropriate. The oncologist may review HER2 status, ER and PR status, tumour grade, cancer stage, lymph node involvement, previous treatment, genetic testing results and other molecular biomarkers when relevant.

Some targeted treatments are used in early-stage disease to reduce recurrence risk. Others are mainly used when cancer has spread or returned. A targeted medicine should not be prescribed simply because it is newer or more expensive. See breast cancer stages and treatment options for how sequencing fits the wider plan.

HER2 stands for human epidermal growth factor receptor 2. It is a protein involved in cell growth and division. Some breast cancer cells produce excessive amounts of HER2 or have an increased number of copies of the HER2 gene. These cancers are called HER2-positive breast cancers and may respond to medicines that specifically target this protein.

HER2 testing is usually performed on a breast cancer tissue sample obtained through biopsy or surgery. Common tests include immunohistochemistry (IHC), which measures HER2 protein, and in situ hybridisation (ISH), which examines HER2 gene copies. Full testing pathways are covered in the breast cancer diagnosis guide and ER, PR and HER2 guide.

Some cancers that are not classified as HER2-positive may show low levels of HER2 protein — often IHC 1+ or IHC 2+ without gene amplification. HER2-low is not the same as conventional HER2-positive disease. Certain antibody-drug conjugates may be considered in specific HER2-low advanced settings, even though standard trastuzumab alone is not appropriate simply because a tumour is HER2-low.

Trastuzumab is one of the most widely used HER2-targeted medicines. It is a monoclonal antibody that attaches to the HER2 protein on cancer cells, interferes with HER2-related signalling and helps the immune system recognise cancer cells.

It may be recommended in early-stage, locally advanced or selected metastatic HER2-positive treatment plans, often with chemotherapy. A typical adjuvant plan aims for about one year of HER2-targeted treatment, although schedules vary. Administration is usually intravenous or, where an approved formulation is appropriate, subcutaneous.

Dedicated pathway detail sits on HER2-positive breast cancer treatment in India.

Pertuzumab is another monoclonal antibody that targets HER2 at a different binding site from trastuzumab. Used together, the two medicines block HER2 signalling more comprehensively than either alone.

Pertuzumab may be included for selected patients with locally advanced, higher-risk early-stage or metastatic HER2-positive disease, often with chemotherapy and trastuzumab. Side effects can include diarrhoea, nausea, fatigue, infusion reactions and potential cardiac effects; accompanying chemotherapy may cause hair loss and low blood counts.

TCHP is a commonly recognised combination for selected patients with HER2-positive breast cancer:

The combination may be used before surgery. Not every HER2-positive patient needs TCHP — stage, tumour characteristics, lymph node status and fitness decide. Neighbouring planning ranges for neoadjuvant chemotherapy and chemotherapy sit on the cost sheets when systemic treatment is part of the plan.

After surgery, the pathologist examines whether residual invasive cancer remains. If residual invasive disease is found after appropriate neoadjuvant HER2-targeted treatment and chemotherapy, the oncologist may recommend a different medicine rather than simply continuing the same plan.

T-DM1 (ado-trastuzumab emtansine) is an antibody-drug conjugate that combines trastuzumab with a chemotherapy-related drug called DM1. It may be recommended after surgery for selected patients with residual invasive HER2-positive disease. Side effects can include fatigue, nausea, low platelets, liver enzyme changes, neuropathy and cardiac effects in selected patients.

Preoperative sequencing is also discussed in the neoadjuvant therapy guide.

Trastuzumab deruxtecan is another antibody-drug conjugate that combines a HER2-targeting antibody with a potent chemotherapy-related drug. It has an important role in selected advanced breast cancer settings, including certain HER2-positive and HER2-low cancers.

Unlike trastuzumab alone, T-DXd also carries a cytotoxic payload into target cells. Possible side effects include nausea, fatigue, hair loss, reduced blood counts, liver enzyme abnormalities and interstitial lung disease or pneumonitis. New cough, breathlessness or fever during treatment needs immediate medical assessment.

Not all targeted therapy is designed for HER2-positive disease. Selected patients with hormone receptor-positive, HER2-negative breast cancer may receive CDK4/6 inhibitors with endocrine therapy. CDK4 and CDK6 help regulate the cell cycle; inhibitors slow cancer cell multiplication.

They should not be treated as interchangeable — approved indications and evidence differ. Endocrine foundations are covered on hormone therapy for breast cancer and the hormone therapy cost sheet.

Yes. Selected patients with higher-risk hormone receptor-positive, HER2-negative early breast cancer may be considered for adjuvant CDK4/6 inhibitor treatment alongside endocrine therapy. Eligibility depends on tumour size, nodes, grade, other high-risk features, estimated recurrence risk, prior treatment and tolerance.

Abemaciclib and ribociclib have evidence and indications in selected early-stage settings with different criteria. Palbociclib should not automatically be substituted in the adjuvant setting.

PARP inhibitors interfere with proteins involved in DNA repair. Cancer cells with certain inherited BRCA1 or BRCA2 mutations may already have DNA-repair defects; PARP inhibitors can push those cells further towards cell death.

Side effects may include nausea, fatigue, anaemia, low white cells or platelets and reduced appetite. Rare bone marrow disorders require monitoring.

Antibody-drug conjugates (ADCs) combine an antibody with a cancer-killing drug so treatment can be directed more selectively — though healthy tissue can still be affected. Breast cancer examples include T-DM1, trastuzumab deruxtecan and sacituzumab govitecan.

Sacituzumab govitecan targets Trop-2 and carries SN-38. It may be used in selected advanced breast cancers, including certain triple-negative and hormone receptor-positive, HER2-negative settings after prior treatment. Side effects can include diarrhoea, nausea, low white cells, fatigue, hair loss and reduced appetite.

This is a simplified overview, not a prescription. Compare options against breast cancer treatment options and the breast cancer treatment in India pathway.

The aim is generally to reduce recurrence risk after surgery and other indicated treatment. Examples include trastuzumab-based treatment, pertuzumab for selected higher-risk HER2-positive cases, T-DM1 after residual invasive disease, selected adjuvant CDK4/6 inhibitors with endocrine therapy, and olaparib for selected high-risk germline BRCA carriers.

When cancer has spread, treatment aims to control disease, relieve symptoms and maintain quality of life. Options may include HER2 antibodies, HER2-directed ADCs, CDK4/6 inhibitors, PARP inhibitors and other medicines selected by molecular testing and prior therapy.

Not every patient requires every test. The oncologist selects investigations based on the proposed medicine. See also the diagnosis tests guide.

Monitoring may include symptoms, examination, blood tests, imaging, selected tumour markers, heart function where relevant and treatment-related side effects. In metastatic disease, imaging helps assess response, stability or progression. A medicine may be continued, changed or stopped depending on effectiveness and tolerability.

More detail is collected on targeted therapy side effects. Patients should report new or worsening symptoms promptly.

There is no single cost for targeted breast cancer treatment. Expense depends on the exact medicine, brand or approved biosimilar, dose, number of cycles or months, whether chemotherapy is combined, hospital administration charges, laboratory monitoring, imaging, cardiac assessments and side-effect management.

These GAF figures are partner planning ranges from the live cost sheets — not hospital quotations and not a promise that every medicine falls inside the band. Read the full breast cancer treatment cost guide for wider pathway context.

For certain biological medicines, approved biosimilar formulations may be available. A biosimilar is highly similar to an approved reference medicine with no clinically meaningful differences in safety, purity and potency. Patients should not switch brands without consulting their oncologist.

Patients from Tanzania, Kenya, Uganda, Ethiopia, Zambia, Iraq, Oman and other regions may seek consultations for biomarker-defined breast cancers. Reviewing records before travel is especially important because targeted therapy depends on accurate pathology.

Practical travel sequencing is covered in breast cancer treatment in India for international patients. City filters for Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad medical oncologists help shortlist campuses.

Targeted therapy uses medicines that act on specific proteins, receptors or molecular pathways involved in cancer growth. The medicine is selected according to the tumour's biological characteristics.

No. Targeted treatment is appropriate only for selected patients whose cancer has the relevant biomarker or molecular feature.

Trastuzumab is one of the main HER2-targeted medicines. Pertuzumab, T-DM1 and trastuzumab deruxtecan may also be used in specific treatment settings.

No. Trastuzumab is a monoclonal antibody and a HER2-targeted medicine. It may be administered alongside chemotherapy, but it is not a conventional chemotherapy drug.

Both medicines target HER2, but they attach to different regions of the protein and interfere with its activity in different ways. They may be combined in selected treatment plans.

T-DM1 is an antibody-drug conjugate combining trastuzumab with a chemotherapy-related drug. It may be used for selected HER2-positive patients, including those with residual invasive disease after preoperative treatment.

Trastuzumab deruxtecan is an antibody-drug conjugate used in selected advanced HER2-positive and HER2-low breast cancer settings. Lung inflammation is an important risk that needs prompt medical review.

They are targeted medicines that interfere with proteins involved in cell division. Palbociclib, ribociclib and abemaciclib are examples used in selected hormone receptor-positive, HER2-negative breast cancer settings.

They are primarily used in hormone receptor-positive, HER2-negative breast cancer treatment. They are not standard substitutes for HER2-targeted medicines.

PARP inhibitors interfere with DNA repair pathways. Olaparib and talazoparib may be used in selected patients with qualifying BRCA1 or BRCA2 mutations.

They are different treatments and are often used together. Targeted therapy is not automatically better than chemotherapy. The choice depends on the cancer subtype and treatment goal.

Duration varies. Some HER2-targeted adjuvant treatment plans aim for approximately one year. CDK4/6 inhibitors and other targeted medicines have different schedules, depending on the clinical setting.

GAF planning for targeted therapy is $8,000–$30,000 and for molecular targeted therapy $10,000–$32,000. Final cost depends on the exact medicine, dose, duration, monitoring and whether chemotherapy is combined.

Approved biosimilars are available for certain biological cancer medicines. The treating oncologist should confirm whether a particular biosimilar is appropriate.

Yes, subject to hospital acceptance, medical assessment and applicable travel requirements. Patients should share pathology, biomarker and previous treatment reports before travelling.

HER2-low usually describes IHC 1+ or IHC 2+ without gene amplification. It is not the same as conventional HER2-positive disease, but selected antibody-drug conjugates may apply in specific advanced settings.

Common tests include ER/PR, HER2 IHC with ISH when needed, blood counts, liver tests and, for some medicines, echocardiogram, ECG or germline BRCA testing.

Targeted therapy has expanded treatment options for different types of breast cancer. HER2-targeted medicines such as trastuzumab and pertuzumab are important for HER2-positive disease. CDK4/6 inhibitors may benefit selected hormone receptor-positive, HER2-negative patients. PARP inhibitors may be appropriate when inherited mutations qualify. Antibody-drug conjugates add further options in selected advanced settings.

Usefulness depends on accurate biomarker testing, stage, previous treatment and overall health. Patients considering treatment in India should ask why a medicine is recommended, how long it may be needed, what monitoring is required and what the complete cost is likely to be. The right treatment is not necessarily the newest or most expensive medicine — it is the one supported by the diagnosis and clinical evidence.

Medical disclaimer: This article is for educational purposes and does not replace an individual consultation with a qualified medical oncologist. Targeted medicines, treatment combinations and duration must be selected according to validated biomarker results, cancer stage, previous treatment and applicable clinical guidelines. Availability and regulatory approval may differ between countries. Cost estimates must be obtained directly from the treating hospital or pharmacy.